LOCATION

Department of Neurosurgery, West Wing, Level 3, John Radcliffe Hospital, Oxford OX3 9DU

James FitzGerald studied Physics at Oxford University, then Medicine, also at Oxford. He trained in Neurosurgery in Nottingham and Cambridge.  After obtaining a PhD in Neuroelectronic Interfacing at Cambridge University he returned to Oxford and now holds an academic faculty position in the Nuffield Department of Surgical Sciences and a Consultant appointment in Neurosurgery at the John Radcliffe Hospital. He leads the Oxford Neural Interfacing Group and his clinical practice is in Neuromodulation for Movement Disorders and Chronic Pain.

I work on implanted and non-invasive electronic devices that interface directly with parts of the nervous system.

At present my main research focus is on the development of a novel type of interface capable of recording signals from motor axons in severed peripheral nerves after amputation, with the aim of using these signals to control sophisticated prosthetic limbs.

This requires advances in several areas including polymer microfabrication techniques, implantable electrophysiological recording systems, microsurgical implantation methods, and the development of multichannel signal processing and pattern recognition algorithms. A further problem is that like virtually all surgical implants, interfaces evoke a foreign body response that leads to the deposition of scar tissue on their surfaces, which leads to gradual electrical failure of the device. A major strand of my work at present concerns the development of techniques for long term scar suppression, and I have recently shown that drug elution is a very promising approach to this (see Journal of Neural Engineering 2016;13:026006 for further details).

I am also a consultant neurosurgeon in Oxford Functional Neurosurgery, which has the UK's largest clinical practice in deep brain stimulation, spinal cord and dorsal root ganglion stimulation and peripheral nerve stimulation, for the treatment of movement disorders and neuropathic pain.  Alongside and closely intertwined with this clinical work we run a research programme investigating the mechanisms by which neuromodulation treatments work and how they can be improved and their use expanded to new indications. 

I am the President of the Neuromodulation Society of the UK and Ireland (NSUKI), and serve on the board of directors of the International Neuromodulation Scoiety, and as section editor for Brain Stimulation of the society's journal, Neuromodulation: Technology at the Neural Interface.

A directional DBS lead in situ in the subthalamic nucleus, imaged with ultra-high resolution photon counting CT.